Real-World Effectiveness and Safety of Isavuconazole Versus Amphotericin B for Patients with Invasive Mucormycosis
Microorganisms · 01.01.2025 · 13 (1) · 55
DOI: 10.3390/microorganisms13010055 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microorganisms, online erschienen am 01.01.2025. Verfasst von Jiayuan Qin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center of Infectious Diseases, West China Hospital, Sichuan University, Guoxuexiang 37, Chengdu 610041, China. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China.
Abstract (Originalsprache)
Background
Invasive mucormycosis (IM) poses a substantial morbidity and mortality burden among immunocompromised patients.
Objectives
We aim to compare the real-world effectiveness and safety of isavuconazole with those of amphotericin B in patients with IM. Patients and methods: In this observational cohort study, we enrolled patients who were diagnosed with IM and treated with either isavuconazole or amphotericin B.
Results
A total of 106 patients met the study criteria. Of these, 47 received isavuconazole, and 59 received amphotericin B as the primary treatment. The two cohorts had similar baseline characteristics, including a history of malignancy, use of immunosuppressants, infection sites, and pathogens. The amphotericin B group demonstrated a significantly greater incidence of renal disorders (p < 0.001) and hypokalemia (p < 0.001) than the isavuconazole group. The proportion of patients who received salvage therapy was greater in the amphotericin B group than in the isavuconazole group (42% vs. 6%, p < 0.001). Eighteen patients in the amphotericin B group discontinued treatment because of adverse events, whereas no patients in the isavuconazole group discontinued treatment because of adverse events. A significant difference in the primary therapeutic response between the isavuconazole and amphotericin B groups was noted (p = 0.013), with a higher treatment failure rate in the amphotericin B group (68% vs. 36%, p = 0.001). However, there were no significant differences in all-cause mortality or mucormycosis-attributable mortality rates between the two groups.
Conclusions
Isavuconazole outperformed amphotericin B as a first-line treatment option for IM in terms of its clinical effectiveness and safety.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center of Infectious Diseases, West China Hospital, Sichuan University, Guoxuexiang 37, Chengdu 610041, China.
- State Key Laboratory of Biotherapy, Division of Infectious Diseases, Chengdu 610041, China.
- Center for Pathogen Research, West China Hospital, Sichuan University, Chengdu 610041, China.
ORCID-Profile: Jiayuan Qin, Xiaoju Lv, Yanbin Liu
Förderung
- National Key Research and Development Program of China
Zitieren
APA
Qin, J., Bi, H., Tang, G., Liu, X., Qu, J., Lv, X., & Liu, Y. (2025). Real-World Effectiveness and Safety of Isavuconazole Versus Amphotericin B for Patients with Invasive Mucormycosis. Microorganisms, 13(1), 55. https://doi.org/10.3390/microorganisms13010055
Vancouver
Qin J, Bi H, Tang G, Liu X, Qu J, Lv X, et al. Real-World Effectiveness and Safety of Isavuconazole Versus Amphotericin B for Patients with Invasive Mucormycosis. Microorganisms. 2025;13(1):55. doi:10.3390/microorganisms13010055
BibTeX
@article{Qin2025,
author = {Qin, Jiayuan and Bi, Hongxia and Tang, Guangmin and Liu, Xinyao and Qu, Junyan and Lv, Xiaoju and Liu, Yanbin},
title = {Real-World Effectiveness and Safety of Isavuconazole Versus Amphotericin B for Patients with Invasive Mucormycosis},
journal = {Microorganisms},
year = {2025},
volume = {13},
number = {1},
pages = {55},
doi = {10.3390/microorganisms13010055}
}
EUVIMED